Page 6 - Propharma Group News Today

BioPharma

Food industry news, voices and jobs. Optimized for your mobile phone.

Overland Park, Kansas (PRWEB) October 06, 2021 -- October 6, 2021, (Overland Park, KS) — ProPharma Group, a portfolio company of Odyssey Investment Partners,

ProPharma Group, a portfolio company of Odyssey Investment Partners, has acquired Pharmica Consulting, a life science consulting company.

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented pooled placebo data from multiple studies in which the results confirmed the clinical...

Sign In " regErrorContainer.innerHTML = RegErrorMsg return } var passwordlessData = { identifiers: { email_address: email }, delivery: { method: email, destination: email, action: login, redirect: window.location.href.replace(window.location.origin, "") } }; ...

Crain's Health Pulse is your source for actionable, exclusive and inside news on the health care industry.

ProPharma Group and The Planet Group Announce Agreement to Merge Share Article ProPharma Group and The Planet Group have reached a definitive agreement to merge the two companies. The complementary nature of this merger creates a dynamic platform with a truly global footprint and a complete line of service offerings to meet all of our clients’ needs. We are looking forward to the next phase of growth and our continued commitment to quality and excellence in everything we do. ...

ProPharma Group Announces the Acquisition of Diamond Pharma Services News provided by Share this article Share this article OVERLAND PARK, Kan., March 2, 2021 /PRNewswire/ -- ProPharma Group, a portfolio company of Odyssey Investment Partners, announces the acquisition of Diamond Pharma Services.  Diamond Pharma Services provides regulatory affairs, pharmacovigilance, and compliance & quality services to support pharmaceutical and biotechnology companies in obtaining and maintaining medicinal...

In the fall of 2016, Alnylam Pharmaceuticals was looking to expand. The Cambridge, Massachusetts–based company had therapies based on RNA interference (RNAi) technology in late-stage clinical testing for a handful of rare diseases, and wanted to establish a presence in Europe to better serve patients there. By the end of the following year, the company had opened offices in Maidenhead, UK; Zug, Switzerland; and Amsterdam, the Netherlands, to serve as its three European hubs. Scouting for new ...